Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC »

[at noodls] – More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression[1] Separate data show 35% of TSC patients treated with everolimus had their … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view